We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Reference sheet · Neuropeptides · CPC catalog code NEUP-122
This sequence carries terminal or reporter modifications (Glp, NH2), so no molecular formula or weight is published here — the modified mass must come from the lot certificate of analysis. Residue composition and charge describe the peptide backbone only. Composition figures above are derived arithmetically from the published sequence for the unmodified free peptide. Salt forms (commonly trifluoroacetate or acetate), amidation, and other modifications shift the observed mass — always reconcile against the current lot certificate of analysis.
Volumes for a 1 mg vial of Physalaemin at common working concentrations. Add solvent slowly down the vial wall and swirl — do not vortex or shake.
Reference standards in the Neuropeptides class are typically shipped as lyophilized powder and stored desiccated at −20 °C protected from light. Once reconstituted in bacteriostatic water or the assay-appropriate buffer, aliquot and store at −80 °C to minimize freeze–thaw cycles. Confirm handling requirements against your institutional biosafety and radiation protocols before use.
Physalaemin sits within the Neuropeptides research class (CPC reference NEUP-122). Neuropeptides bind GPCRs expressed on central and peripheral neurons — modulating cAMP, calcium, and β-arrestin signaling to shape neurotransmission, network excitability, and behavior. Investigators typically incorporate Physalaemin as a reference standard, tool ligand, or substrate in the assay contexts listed above. Radioligand binding, cAMP HTRF, calcium mobilization, and in vivo behavior assays.
Physalaemin (CPC catalog code NEUP-122) is a synthetic neuropeptide receptor ligand in the neuropeptides category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.
Published and internal research programs use Physalaemin as a reference standard in neuropeptides workflows — for example, gpcr receptor-binding and functional profiling and behavioral pharmacology (rodent models). Human clinical evidence is not established.
No. Physalaemin is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.
In a neuropeptides workflow, Physalaemin is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Radioligand binding, cAMP HTRF, calcium mobilization, and in vivo behavior assays.
Other reference standards in the same class — commonly cross-referenced during assay design and comparator selection.